<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2014921</article-id><article-id pub-id-type="pmcid-ver">PMC2014921.1</article-id><article-id pub-id-type="pmcaid">2014921</article-id><article-id pub-id-type="pmcaiid">2014921</article-id><article-id pub-id-type="pmid">10718777</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00162.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacokinetics/Pharmacodynamics</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Davis</surname><given-names initials="TME">Timothy M E</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daly</surname><given-names initials="F">Frank</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walsh</surname><given-names initials="JP">John P</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ilett</surname><given-names initials="KF">Kenneth F</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beilby</surname><given-names initials="JP">John P</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dusci</surname><given-names initials="LJ">Leon J</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barrett</surname><given-names initials="PHR">P Hugh R</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><aff id="au1"><label>1</label><institution>University of Western Australia, Department of Medicine, Fremantle Hospital</institution><addr-line>Fremantle, Western Australia, Australia</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Pharmacology, University of Western Australia</institution><addr-line>Nedlands, Australia</addr-line></aff><aff id="au3"><label>3</label><institution>Clinical Biochemistry, Clinical Pharmacology and Toxicology Laboratories, The Western Australian Centre for Pathology and Medical Research</institution><addr-line>Nedlands, Australia</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Correspondence: Professor T. M. E. Davis, University of Western Australia, Department of Medicine, Fremantle Hospital, PO Box 480, Fremantle, Western Australia 6959, Australia. Tel.: (618) 9431 3229. Fax: (618) 9431 2977. E-mail: <email>tdavis@cyllene.uwa.edu.au</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2000</year></pub-date><volume>49</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">151577</issue-id><fpage>223</fpage><lpage>230</lpage><history><date date-type="received"><day>16</day><month>7</month><year>1999</year></date><date date-type="accepted"><day>16</day><month>12</month><year>1999</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2010-12-24 12:37:25.763"><day>24</day><month>12</month><year>2010</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0049-0223.pdf"/><abstract><sec><title>Aims</title><p>Gliclazide pharmacokinetics and pharmacodynamics were assessed in 9 Caucasians and 10 Australian Aborigines with uncomplicated type 2 diabetes.</p></sec><sec sec-type="methods"><title>Methods</title><p>Subjects were on a stable dose of 80 mg gliclazide twice daily, took 160 mg on the morning of study and had a standard breakfast. No further gliclazide was given over the next 48 h. Regular blood samples were drawn for serum glucose, insulin and gliclazide assay. Gliclazide was measured using h.p.l.c. Noncompartmental analysis was used to describe primary data. A multicompartment model incorporating entero-hepatic recirculation was fitted to group mean serum gliclazide profiles.</p></sec><sec><title>Results</title><p>The Caucasians were older than the Aborigines (mean &#177; s.d. age 53.4 &#177; 12.2 <italic>vs</italic> 40.3 &#177; 6.9 years, <italic>P</italic> &lt; 0.05) but had similar diabetes duration, body mass index and glycated haemoglobin. Noncompartmental analysis revealed no between-group differences in gliclazide kinetics. Post-breakfast serum glucose and insulin responses were also similar apart from a longer time to maximum concentration (<italic>t</italic><sub>max</sub>) for glucose amongst the Aborigines (2.6 &#177; 0.4 vs 2.2 &#177; 0.3 h in Caucasians; <italic>P</italic> = 0.024). Gliclazide <italic>t</italic><sub>max</sub> exhibited a skewed unimodal distribution and was not associated with gliclazide maximum concentration, or glucose or insulin responses. Most patients had a serum gliclazide profile suggestive of enterohepatic recirculation and/or biphasic absorption. Model-derived estimates of the extent of putative enterohepatic recirculation were 30% and 20% of dose in Caucasians and Aborigines, respectively.</p></sec><sec><title>Conclusions</title><p>Gliclazide is equally effective in Caucasian and Aboriginal diabetic patients. The pharmacokinetics of oral gliclazide appear more complex than previously thought. Gliclazide pharmacodynamics are unrelated to rate and extent of absorption, consistent with a threshold concentration for hypoglycaemic effect.</p></sec></abstract><kwd-group><kwd>Australian Aborigines</kwd><kwd>Caucasians</kwd><kwd>gliclazide</kwd><kwd>pharmacodynamics</kwd><kwd>pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>